Rotating Christmas Village Tree, Military Helicopters Flying Over My House Today 2022, Are Bidens Poisonous To Dogs, Articles B

Bristol Myers Squibb Employee Benefit: Paid Holidays Bristol Myers Squibb expects repotrectinib to be approved in the U.S. in the second half of 2023 and become a new standard of care for patients with ROS1-positive NSCLC in the first-line setting. Celestica - Ireland. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. Learn about our safety approach to COVID-19 > At Bristol Myers Squibb, the work you do-often in support of emerging therapeutic areas that require new methods of thinking and working-will help people prevail over serious diseases. 0000115702 00000 n Written by Zacks Equity Research for Zacks ->. 0000011978 00000 n We are proud of our companys global commitment to Inclusion & Diversity and the meaningful steps we are taking to drive equitable advancement and outcomes for all. These statements are likely to relate to, among other things, the companys ability to execute successfully its strategic plans, including its business development strategy and capital allocation strategy, planned product launches and updates, expectations relating to its pipeline and in relation to its ability to realize the projected benefits of the Celgene acquisition and the MyoKardia acquisition, the full extent of the impact of the COVID-19 pandemic on the companys operations and the development and commercialization of its products, potential laws and regulations to lower drug costs, market actions taken by private and government payers to manage drug utilization and contain costs, the expiration of patents or data protection on certain products, including assumptions about the companys ability to retain patent exclusivity of certain products, and the impact and the result of governmental investigations. Warnings Bristol-Myers Squibb Co and Eisai Co said on Thursday they had entered into an agreement worth up to $3.10 billion to jointly develop and market an experimental cancer drug. The transaction was unanimously approved by both the Bristol Myers Squibb and Turning Point Therapeutics Boards of Directors and is anticipated to close during the third quarter of 2022. Bristol-Myers Squibb 2021: Mark Your Calendar. 07/29/21 : Interim 2021 Earnings Release (Projected) 10/28/21 : Q3 2021 Earnings Release (Projected) 01/27/22 : FY 2021 Earnings Release (Projected) 04/28/22 Bristol-Myers would pay $650 million, including for research and development expenses to Eisai, which will also be eligible for up to $2.45 billion in milestone payments, the companies said. Form NPORT-P Short-Term Bond Fund of For: May 31 These documents will be available at no charge on the SECs website at www.sec.gov. The website may also contain certain non-GAAP financial measures, adjusted to include certain costs, expenses, gains and losses and other specified items.